Home Companies Catalysts Deep Dives
Lupkynis voclosporin APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaImmunology
Launch2021-01-22
Peak Sales Est$400M
Formulations[{"id":"lupkynis-oral","route":"ORAL","device":"Capsule (7.9mg)","setting":"PATIENT_SELF","frequency
Companies
AUPH (ORIGINATOR)100%
4578 (LICENSEE)0%
Mechanism: Calcineurin inhibitor
Expert: Calcineurin inhibitor blocking T-cell activation for transplant immunosuppression.
Everyday: Suppresses immune system to prevent organ rejection.
Targets: ["CALCINEURIN"]
Programs (1)
IndicationStageKey StudyRegional Status
Lupus NephritisAPPROVEDAURORA[{"stage":"APPROVED","region":"US","label_notes":"Aurinia holds US rights","appr
Notes
Aurinia-originated. Otsuka has ex-US rights (EU, Japan, UK). Calcineurin inhibitor for active lupus nephritis.
Data from Supabase · Updated 2026-03-24